Drug Profile


Alternative Names: 3GS; Glucoronylglucosaminoglycan sulphate; KRX-101; Sulodexide Gelcaps; Sulonex; Vessel

Latest Information Update: 05 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Alfa Wassermann SpA
  • Developer Alfa Wassermann SpA; Keryx Biopharmaceuticals
  • Class Antihyperlipidaemics; Antithrombotics; Glycosaminoglycans
  • Mechanism of Action Glycosaminoglycan stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Thrombosis; Vascular disorders
  • Phase III Venous insufficiency; Venous thromboembolism
  • Discontinued Diabetic nephropathies; Glomerulonephritis; Kidney disorders; Pulmonary fibrosis

Most Recent Events

  • 19 Sep 2016 Phase-III clinical trials in Venous insufficiency in Poland (PO) (EudraCT2016-000783-42)
  • 27 Mar 2008 Discontinued - Phase-III for Diabetic nephropathies in Australia (PO)
  • 27 Mar 2008 Discontinued - Phase-III for Diabetic nephropathies in Hong Kong (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top